A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis
Calvo-Barreiro, Laura (Universitat Autònoma de Barcelona)
Eixarch, Herena (Universitat Autònoma de Barcelona)
Ponce-Alonso, Manuel (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid))
Castillo, Mireia (Universitat Autònoma de Barcelona)
Lebrón-Galán, Rafael (Hospital Nacional de Parapléjicos (Toledo))
Mestre, Leyre (Instituto Cajal (Consejo Superior de Investigaciones Científicas))
Clemente, Diego (Grupo de Neuroinmuno-Reparación, Unidad de Investigación, Hospital Nacional de Parapléjicos, Finca "La Peraleda" s/n, 45071 Toledo, Spain)
del Campo, Rosa (Hospital Universitario Ramón y Cajal (Madrid))
Montalban, Xavier (Universitat Autònoma de Barcelona)
Espejo, Carmen (Universitat Autònoma de Barcelona)
Instituto Cajal (Madrid)

Fecha:	2020
Resumen:	Previous studies in experimental autoimmune encephalomyelitis (EAE) models have shown that some probiotic bacteria beneficially impact the development of this experimental disease. Here, we tested the therapeutic effect of two commercial multispecies probiotics-Lactibiane iki and Vivomixx-on the clinical outcome of established EAE. Lactibiane iki improves EAE clinical outcome in a dose-dependent manner and decreases central nervous system (CNS) demyelination and inflammation. This clinical improvement is related to the inhibition of pro-inflammatory and the stimulation of immunoregulatory mechanisms in the periphery. Moreover, both probiotics modulate the number and phenotype of dendritic cells (DCs). Specifically, Lactibiane iki promotes an immature, tolerogenic phenotype of DCs that can directly induce immune tolerance in the periphery, while Vivomixx decreases the percentage of DCs expressing co-stimulatory molecules. Finally, gut microbiome analysis reveals an altered microbiome composition related to clinical condition and disease progression. This is the first preclinical assay that demonstrates that a commercial probiotic performs a beneficial and dose-dependent effect in EAE mice and one of the few that demonstrates a therapeutic effect once the experimental disease is established. Because this probiotic is already available for clinical trials, further studies are being planned to explore its therapeutic potential in multiple sclerosis patients.
Ayudas:	Ministerio de Economía y Competitividad PI15/00840 Ministerio de Economía y Competitividad PI18/00357 Ministerio de Economía y Competitividad RD16/0015/0044 Ministerio de Economía y Competitividad RD16/0015/0019
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Gut microbiota ; Probiotics ; Immune regulation ; Experimental autoimmune encephalomyelitis ; Multiple sclerosis ; Adaptive immunity ; Antigen presenting cells ; Gut microbiome ; Gut permeability
Publicado en:	Cells, Vol. 9 (april 2020) , ISSN 2073-4409

DOI: 10.3390/cells9040906
PMID: 32272791

22 p, 4.1 MB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados